Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application for its Krazati (adagrasib) product.

This application covers this product in combination with cetuximab as a targeted treatment option in patients with previously treated locally advanced or metastatic KRAS G12C mutation-positive colorectal cancer.

The FDA has set a target action date of June 21 for this application, which is based on the results of the phase 1/2 KRYSTAL-1 trial, which showed Krazati to be well tolerated and to offer promising clinical activity in relevant patients.

Copyright (c) 2024 All rights reserved.